InferVision Secures Series D1 Funding Led by Zhongguancun M&A Fund with Participation from National Team Investors

On November 24, Infervision Medical Technology Co., Ltd. (hereinafter referred to as “Infervision”) announced the completion of its Series D1 financing round, with investment from multiple state-backed institutions based in Beijing, Shanghai, and Shenzhen.

This round of financing was led by the Zhongguancun M&A Fund of Funds, with follow-on investments from Zhongguancun Science City, Shenzhen Yicun Tongsheng, Shanghai Lianyi, and existing shareholders. Among them, Shenzhen Yicun Tongsheng is a joint investment platform capitalized by Shenzhen OCT Group, Shenzhen Government Guidance Fund, Shenzhen Qianhai Industrial Guidance Fund, and Yicun Capital. Shanghai Lianyi is a joint investment platform capitalized by the Shanghai State-owned Assets Supervision and Administration Commission, Shanghai International Airport Co., Ltd., Shanghai Pharmaceutical Group, Shanghai Information Investment Co., Ltd., and Shanghai Science and Technology Innovation Fund.

Artificial intelligence is a key driving force behind the new round of technological and industrial revolutions. The Fifth Plenary Session of the 19th Central Committee of the Communist Party of China highly emphasized the core position of innovation in the overall modernization drive, charting a blueprint for innovative development during the 14th Five-Year Plan period and beyond. As pioneers in industrial innovation, China’s artificial intelligence and life sciences sectors are poised for a new wave of explosive growth. AI healthcare, spanning these two critical domains, is set to embrace significant historical opportunities. At this juncture, the entry of top-tier national teams into Infervision reflects governmental recognition and support for outstanding enterprises. Driven by premier national resources, the AI healthcare sector is approaching a new turning point. Represented by Infervision, AI healthcare companies will seize this historic opportunity to achieve greater breakthroughs in the field of artificial intelligence in medicine, while fulfilling their commitment to continuously improving life and health through advanced technology.

As a high-tech enterprise specializing in AI-driven medical innovation, Infervision upholds the belief of “building a community of shared health for humanity with AI.” Leveraging deep learning technology, Infervision has developed an end-to-end medical AI platform that includes an AI deployment management platform, an AI big data mining and research platform, and an AI clinical application platform. The company creates medical AI products for quality control, health management, and scientific research innovation, delivering advanced and intelligent services to governments, healthcare institutions, physicians, and patients, truly realizing the mission of “AI Improving Life and Health.”

Infervision will deepen its "One Horizontal, One Vertical" strategy in the future: Vertically, AI will assist in comprehensively improving the quality and efficiency of every link in clinical pathways for each disease, intervening in diseases from the perspective of the entire course of screening, diagnosis, treatment, and management; horizontally, it will expand to cover common diseases, such as cancer, cardiovascular and cerebrovascular diseases, and infectious diseases.

Just 10 days ago, Infervision’s AI product for pulmonary nodules received Class III medical device certification from the National Medical Products Administration (NMPA), becoming the only lung-related AI product approved by the NMPA. Infervision has thus become the world’s first AI healthcare company to hold certifications from all four major medical markets: China’s NMPA, the U.S. FDA, Japan’s PMDA, and Europe’s CE.